此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

使用 Neurolyser XR 治疗与骶髂关节炎相关的腰痛

2026年11月5日 更新者:FUSMobile Inc.

Neurolyser XR 治疗与骶髂关节炎相关的腰痛的安全性和有效性

The Neurolyser XR is a device used to deliver high-intensity focused ultrasound for the ablation of the lateral sacral branch nerve in patients with Sacroiliitis.

研究概览

详细说明

The sacroiliac joint connects the sacrum (a triangle shaped bone) with the iliac bone on both sides of the lower spine. These joints transmit all the forces from the upper body to the pelvis and their respective legs. Repeated trauma and aging affect this joint resulting in inflammation and arthritic changes. These changes result in misalignment of the joint or limitation to normal motion which can create pain typically very low in the back or in the buttocks,

High-Intensity Focused Ultrasound (HIFU) technology uses sound waves. These sound waves are concentrated into a specific spot in order to raise the local tissue temperature causing a burn, this burn is expected to intentionally damage the nerve causing pain.

The HIFU device used in this study is called, the Neurolyser XR. It focuses sound wave energy directly on the nerve of the painful sacroiliac joint, causing an increase in temperature, which is expected to directly damage the nerve fibers which carry pain signals to the brain.

研究类型

介入性

注册 (估计的)

10

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Virginia
      • Charlottesville、Virginia、美国、22903
        • University of Virginia, Department of Anesthesiology

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Men and women aged 18 and older
  2. BPI < 40
  3. Patients who are able and willing to give consent and able to attend all study visits.
  4. Patients who are able to communicate with the treating physician.
  5. Patients must have chronic lower back pain (LBP) attributed to degenerative sacroiliitis diagnosed by a pain physician using the following guidelines:
  6. At least 1 positive sacroiliac joint provocation test (Gaeslen's test, FABER (Patrick's test), and pelvic rock)
  7. Back pain predominantly below L5
  8. 50% relief following either sacroiliac joint (SI) joint injection and/or lateral branch blocks corresponding to the expected duration of the medication utilized. (i.e SI joint injection-expected pain relief duration of steroid, lateral branch blocks-expected pain relief duration of local anesthetic utilized).
  9. All other possible sources of low back pain have been ruled out as the primary pain generator, including but not limited to: the intervertebral discs, bone fracture, the zygapophyseal joints, the hip joint, symptomatic spondylolisthesis, tumor, and other regional soft tissue structures (this is done by physical exam, medical history, and MRI/CT/X-ray as required)
  10. Patients with NRS (0-10 scale) LBP average score ≥ 4
  11. Patients with chronic LBP for at least 12 months.
  12. Patients with Oswestry Disability Questionnaire (ODQ) for LBP score > 40%

Exclusion Criteria:

  1. Patients on dialysis
  2. Patients with evidence of lumbosacral radiculopathy on MRI, CT or physical exam findings, including radicular leg pain (symptomatic moderate or severe foraminal or central canal stenosis).
  3. Spinal pathology that may impede recovery such as spina bifida occulta, grade II or higher.
  4. Spondylolisthesis at L5/S1, or scoliosis
  5. Patients with radiofrequency ablation (RF/RFA) treatment for sacroiliitis LBP
  6. Patients with bilateral sacroiliitis LBP
  7. Patients with previous low back surgery
  8. Patients who are pregnant
  9. Patients with existing malignancy
  10. Patients with allergies to relevant anesthetics
  11. Patients with motor deficit or any other indication for surgical intervention
  12. Patients with contraindications for MRI
  13. Patients with an acute medical condition (e.g., pneumonia, sepsis, systemic infection, uncontrolled immunosuppression-AIDS, cancer, DM) that is expected to hinder them from completing this study.
  14. Patients with unstable cardiac status including:
  15. Unstable angina pectoris on medication
  16. Patients with documented myocardial infarction less than 40 days prior to protocol enrolment
  17. Patients with Severe Congestive Heart Failure, New York Heart Association (NYHA) class 4.
  18. Patients on anti-arrhythmic drugs or with uncontrolled and/or untreated arrhythmia status
  19. Patients with severe cerebrovascular disease (CVA within last 6 months)
  20. Patients with severe hypertension (diastolic BP > 100 on medication)
  21. Patient Body Mass Index > 45 or <20
  22. Patients with known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease
  23. Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.
  24. The patient is unable to communicate with the investigator and staff.
  25. Patients who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hours)
  26. Patient with acute pelvic inflammatory conditions
  27. Ongoing/ unresolved Worker's compensation, injury litigation, military medical board, or disability remuneration claims
  28. Morphine Milligram Equivalents (MME) > 60 per 24 hrs.
  29. Patients with platelets < 100.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:HIFU for Sacroiliitis

High-intensity focused ultrasound delivered to the lateral sacral branch nerve for neurolysis.

HIFU is delivered via a non-invasive ultrasonic transducer, through a gel pad for acoustic coupling, into the patients body in a precise manner focused on the lateral sacral branch nerves.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v6.0.
大体时间:Procedure through 6 month follow-up visit

Per the CTCAE assessment, each organ or possible adverse event would be categorized on a scale of 1 to 5 where:

Grade 1 is Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.

Grade 2 is Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL).

Grade 3 is Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.

Grade 4 is Life-threatening consequences; urgent intervention indicated. Grade 5 is Death related to AE.

Procedure through 6 month follow-up visit

次要结果测量

结果测量
措施说明
大体时间
The participants change in level of pain as assessed by the Numerical Rating Scale (NRS) and any change in analgesic/opiate usage.
大体时间:Procedure through 6 month follow-up visit

The pain scale is 0 to 10 where 0 is no pain at all and 10 is the worst pain imaginable

Procedure through 6 month follow-up visit
Change in quality of life will be assessed by Oswestry Disability Index (ODI)
大体时间:Procedure through 6 month follow-up visit

ODI scale includes 10 questions, each can score 0 to 5 for a total score of 0 to 50.

scores are interpreted as follows: 0-4: No disability 5-14: Mild disability 15-24: Moderate disability 25-34: Severe disability 35-50: Completely disabled

Procedure through 6 month follow-up visit
Change in quality of life will be assessed also by Brief Pain Inventory (BPI-QOL)
大体时间:Procedure through 6 month follow-up visit

BPI includes 7 questions on the level the patient pain interferes with their daily activities.

Each question can score 0 to 10 for a total score of 0 to 70.

Procedure through 6 month follow-up visit

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Lynn Kohan, MD、University of Virginia Pain Medicine Clinic

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年9月13日

初级完成 (估计的)

2027年5月26日

研究完成 (估计的)

2027年7月15日

研究注册日期

首次提交

2023年9月6日

首先提交符合 QC 标准的

2023年9月21日

首次发布 (实际的)

2023年9月25日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅